Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab as a ...
Abstract: Electric vehicles (EVs) hold great potential as a sustainable mode of transportation. Nevertheless, issues with their effectiveness and safety still exist, particularly with relation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results